Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock opened at $131.81 on Friday. Intra-Cellular Therapies has a fifty-two week low of $64.09 and a fifty-two week high of $131.87. The stock’s 50 day simple moving average is $129.12 and its two-hundred day simple moving average is $99.63. The stock has a market cap of $14.04 billion, a price-to-earnings ratio of -151.50 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, analysts predict that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.

Hedge Funds Weigh In On Intra-Cellular Therapies

Hedge funds have recently bought and sold shares of the business. Cerity Partners LLC grew its stake in shares of Intra-Cellular Therapies by 62.9% in the third quarter. Cerity Partners LLC now owns 44,107 shares of the biopharmaceutical company’s stock worth $3,227,000 after acquiring an additional 17,027 shares during the period. The Manufacturers Life Insurance Company raised its stake in Intra-Cellular Therapies by 1.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock valued at $1,614,000 after buying an additional 283 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Intra-Cellular Therapies by 13.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company’s stock valued at $1,648,000 after buying an additional 2,622 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Intra-Cellular Therapies by 3.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company’s stock worth $23,649,000 after buying an additional 11,104 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Intra-Cellular Therapies in the third quarter worth $2,195,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.